晶华微(688130) - 2025 Q1 - 季度财报

Financial Performance - The company achieved operating revenue of CNY 37,040,423.65, representing a year-on-year increase of 38.70%[4] - The net profit attributable to shareholders was a loss of CNY 10,139,213.96, compared to a loss of CNY 1,142,936.53 in the same period last year[4] - The weighted average return on net assets was -0.80%, a decrease of 0.71 percentage points compared to the previous year[4] - Total operating revenue for Q1 2025 reached ¥37,040,423.65, a 38.6% increase from ¥26,704,868.92 in Q1 2024[22] - The net loss for Q1 2025 was ¥10,139,213.96, compared to a net loss of ¥1,142,936.53 in Q1 2024, indicating a significant decline in profitability[23] - Basic and diluted earnings per share for Q1 2025 were both -¥0.11, compared to -¥0.02 in Q1 2024[23] Research and Development - Research and development expenses totaled CNY 22,286,093.29, an increase of 40.22% year-on-year, with R&D expenses accounting for 60.17% of operating revenue[5][7] - The company plans to focus on expanding its R&D efforts to enhance product offerings and market competitiveness[22] - R&D expenses increased to ¥22,286,093.29 in Q1 2025, compared to ¥15,894,086.36 in Q1 2024, reflecting a 40.0% rise[22] Cash Flow and Liquidity - The company reported a negative cash flow from operating activities of CNY 19,288,867.49, worsening from a negative cash flow of CNY 11,306,272.29 in the previous year[4] - In Q1 2025, cash inflow from operating activities was CNY 49,366,882.23, compared to CNY 30,445,552.39 in Q1 2024, representing an increase of 62.1%[26] - The net cash flow from operating activities was -CNY 19,288,867.49 in Q1 2025, worsening from -CNY 11,306,272.29 in Q1 2024[26] - Cash inflow from investment activities totaled CNY 176,368,509.18 in Q1 2025, down from CNY 242,520,978.19 in Q1 2024, a decrease of 27.3%[27] - The ending cash and cash equivalents balance decreased to CNY 477,519,179.79 in Q1 2025 from CNY 761,254,004.72 in Q1 2024, a decline of 37.3%[27] Assets and Liabilities - The total assets at the end of the reporting period were CNY 1,383,194,526.82, a decrease of 3.12% from the end of the previous year[5] - Total assets decreased to ¥1,383,194,526.82 in Q1 2025 from ¥1,427,803,016.08 in Q1 2024, a decline of 3.1%[20] - Total liabilities decreased to ¥120,786,491.07 in Q1 2025 from ¥162,552,705.21 in Q1 2024, a reduction of 25.7%[20] - The company's equity attributable to shareholders was ¥1,262,408,035.75 in Q1 2025, slightly down from ¥1,265,250,310.87 in Q1 2024[20] Shareholder Information - The company has a significant shareholder structure, with the largest shareholder holding 43.91% of the shares[14] - The top ten shareholders include various entities, with the largest being an individual shareholder[15] - The company has not reported any changes in the lending or borrowing of shares among the top shareholders[16] - There are no known relationships or concerted actions among the other shareholders beyond the disclosed familial ties[15] Operational Highlights - The company successfully introduced new pressure/temperature sensor signal conditioning chips to major clients and achieved small-scale shipments of specialized chips for blood glucose meters[8] - The company expanded its customer base, successfully onboarding several well-known brand clients during the reporting period[9] - The company plans to launch mass production samples of high-performance touch display control chips in the second quarter[7] Inventory and Receivables - Accounts receivable decreased to ¥25,484,331.31 from ¥30,794,936.66, reflecting a reduction in outstanding receivables[18] - Inventory slightly decreased to ¥62,647,380.98 from ¥63,450,190.96, showing stable inventory management[18] - Other current assets totaled ¥228,533,289.93, a slight increase from ¥227,450,968.54[18]